Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio
December 11, 2024
Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.
- Buyers
- Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, Newpath Partners, 5AM Ventures, DCVC Bio, F-Prime Capital, GV (Google Ventures), Janus Henderson Investors, Mubadala Capital, Omega Funds, Sixth Street, Sofinnova Partners, T. Rowe Price, Wellington Management, Alexandria Venture Investments, Casdin Capital, Menlo Ventures, Wilson Sonsini Goodrich & Rosati
- Targets
- Chroma Medicine, Nvelop Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Chemomab Therapeutics and Scipher Medicine to Merge to Advance Nebokitug in AI-Powered RA Trial
July 9, 2026
Healthcare Services
Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement in a stock transaction. The combined company, expected to operate as Scipher Medicine Corporation and trade on Nasdaq, will initially focus on advancing Chemomab’s nebokitug into a Phase 2 rheumatoid arthritis trial using Scipher’s AI Network Medicine platform and PrismRA test.
-
BioCina and NovaCina Announce Strategic Merger to Create Integrated CDMO
January 13, 2025
Healthcare Services
BioCina and NovaCina announced a strategic merger that will create a fully integrated, end-to-end contract development and manufacturing organization (CDMO) under the BioCina name. The combined offering spans cell line and process development through clinical and commercial drug substance manufacturing and sterile fill-finish, leveraging BioCina’s Adelaide capabilities and NovaCina’s Perth sterile fill-finish plant.
-
ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera
November 17, 2023
Healthcare Services
Global private equity healthcare specialist ARCHIMED acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and simultaneously merged them. The resulting Symbio Proinnovera is a dermatology-focused contract research organization (CRO) offering outsourced dermatological therapy formulation and clinical trial testing across the full development lifecycle.
-
Dipharma Inc. Merges Kalexsyn, Inc. into Parent to Complete Integration
January 4, 2022
Pharmaceuticals
Dipharma Inc., part of the Dipharma Group, has merged Kalexsyn, Inc. (a Michigan corporation acquired in 2018) into its 100% owner, Dipharma Inc., effective January 1, 2022. The merger completes Kalexsyn's formal integration and strengthens Dipharma's U.S. cGMP and CRO capabilities in Kalamazoo to support services from discovery through commercialization.
-
Catalyst Clinical Research Merges with Ce3, Inc.
August 5, 2020
Healthcare Services
Catalyst Clinical Research, a NovaQuest-backed CRO headquartered in Wilmington, North Carolina, has merged with Ce3, Inc., an early-phase oncology-focused CRO based in Clinton, Connecticut. The transaction combines Ce3's 15+ years of oncology expertise with Catalyst's broader clinical development and technology capabilities to create a next-generation oncology-focused CRO (add-on to Catalyst's NovaQuest-backed platform).
-
Chroma Color Corporation Acquires Epolin Chemicals
June 3, 2020
Manufacturing
Chroma Color Corporation, a portfolio company of Arsenal Capital Partners, has acquired Epolin Chemicals LLC, a developer and manufacturer of near-infrared (NIR) absorbing dyes and thermoplastic compounds. The acquisition expands Chroma Color’s product portfolio and technical capabilities in NIR dye technology while Epolin will operate as an independent subsidiary to enable cross-selling and continued investment in R&D.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.